Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.36 |
| ▸ | HRH1 | P35367 | 4/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | PAICS | P22234 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19230168 | 0.84 | HRH1 (0.40) | ACACBIRAK4HRH1ROCK1IKBKB | |
| SCHEMBL942192 | 0.78 | HRH1 (0.40) | IRAK4HRH1ROCK1CHRM1IKBKB | |
| Hydrochloric Acid SCHEMBL2773745 | 0.77 | HRH1 (0.39) | IRAK4HRH1ROCK1CHRM1IKBKB | |
| Hydrochloric Acid SCHEMBL2776816 | 0.77 | HTR2C (0.42) | IRAK4HRH1IKBKBAR | |
| SCHEMBL29003859 | 0.76 | HRH1 (0.43) | IRAK4HRH1ROCK1IKBKBROCK2 | |
| SCHEMBL940760 | 0.73 | HRH1 (0.43) | IRAK4HRH1ROCK1IKBKBROCK2 | |
| SCHEMBL27571710 | 0.73 | HRH1 (0.43) | IRAK4HRH1ROCK1IKBKBROCK2 | |
| SCHEMBL26151646 | 0.72 | ACACB (0.40) | ACACB | |
| SCHEMBL24529783 | 0.72 | HRH1 (0.40) | IRAK4HRH1ROCK1IKBKBROCK2 | |
| SCHEMBL19145035 | 0.72 | HRH1 (0.40) | IRAK4HRH1ROCK1IKBKBROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000502-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-19 | — | — | US | disclosed |
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | AR, SHBG, NR5A1 | ACACB 3088/4885IRAK4 3869/4885HRH1 231/4885 |
| US-10000502-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | AR, SHBG, NR5A1 | ACACB 3088/4885IRAK4 3869/4885HRH1 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.